

HLS Therapeutics®

Annual Meeting

June 17, 2022

Forward-looking statements

Certain statements in this presentation are “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always using words or phrases such as “project”, “forecast”, “target”, “expect”, “seek”, “endeavour”, “anticipate”, “plan”, “estimate”, “believe”, “intend”, or stating that certain actions, events or results may, could, should, would, might or will occur or be taken, or achieved) are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of known and unknown risks and uncertainties which would cause actual results or events to differ materially from those presently anticipated. A number of factors could cause actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements could vary materially from those expressed or implied by the forward-looking statements contained in this presentation. These factors should be considered carefully and prospective investors should not place undue reliance on these forward-looking statements. Although the forward-looking statements contained in this presentation are based upon what HLS currently believes to be reasonable assumptions, HLS cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, HLS does not have any obligation to advise any person if it becomes aware of any inaccuracy in or omission from any forward-looking statement, nor does it intend, or assume any obligation, to update or revise these forward-looking statements to reflect new events or circumstances.

- **All figures in USD unless otherwise noted.**
- **Historical financials are per HLS filed quarterly and annual statements**
- **Forward-looking financial estimates are converted at an exchange rate of 1 USD = 1.227 CAD and 1 CAD = 0.80 USD**

Formal Business

1. Presentation of financial statements
2. Election of directors
3. Re-appointment of auditors

Election of Directors

Greg Gubitz, Chair

Gilbert Godin, CEO

Yvon Bastien

Norma Beauchamp

Laura Brege

Don DeGolyer

Rodney Hill

J. Spencer Lanthier

John Welborn

Re-Appointment of Auditors

Ernst & Young LLP



HLS Therapeutics®

Annual Meeting

June 17, 2022

2021 & YTD 2022: Foundation for Growth

Highlights

- 2021 Revenue: $60MM, up 7%
- 2021 Adjusted EBITDA: $26.3MM, up 9%
- 2021 Cash from operations: $16.4MM, up 76%
- Launched MyCare Psychiatry Lab Assays
- Increased Clozaril patient base by 2.5% and grew CSAN Pronto deployments to 56 from 23

Vascepa Highlights

Private payer coverage:
>90% privately covered lives eligible for Vascepa reimbursement

Public payer coverage:
agreed to terms with the pCPA for public reimbursement of Vascepa and achieved public reimbursement in Quebec, effective May 26, 2022

Salesforce expansion:
signed Vascepa co-promotion agreement with Pfizer

Canadian medical society endorsement:
Vascepa included in the guidelines for Canadian Cardiovascular Society, Thrombosis Canada and Canadian Heart & Stroke Foundation

Strong progress towards significant value creation, despite pandemic

Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update

Vascepa: Prescription Momentum Growing



111% Year-over-year increase in Rx

177% Year-over-year increase in prescribing doctors to 2,025

139% Year-over-year increase in patients to 6,945

**year-over-year increase as at March 31, 2022*

Source: Weekly Rx, 2020 - 2022, IQVIA

Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update

HLS Virtual Non-Deal Roadshow

Investor presentation followed by Q&A

Date: June 22, 2022

Time: 12:00pm ET

Access: link available in the Event section of the HLS website

Source: Weekly Rx, 2020 - 2022, IQVIA



HLS Therapeutics®

Annual Meeting

June 17, 2022